Novo diabetes site adds new tools to self-manage

Share this article:
Novo Nordisk has unveiled a revamped diabetes care Web site to communicate with patients seeking help in the self-management of the disease.

ChangingDiabetes-us.com features new tools and content developed in response to findings from the Diabetes Attitudes, Wishes and Needs (DAWN) study, a 5,426-patient survey commissioned by Novo Nordisk.

“The DAWN Study has given us valuable insights into how people cope with diabetes at diagnosis and throughout the disease process,” said Susan Harrow Rago, associate director, patient services & professional relations, in a statement.

According to Rago, the site’s new tools will help diabetes patients collaborate more effectively to develop treatment programs tailored to their individual needs.

Content highlights include:
• Guide Me—a feature allowing diabetes patients to customize the site content based on their personal diagnosis.
• Diabetes Care Plan—an interactive tool that helps users track, manage and set goals for their diabetes care.
• My Priorities—a feature to help patients develop personal diabetes care goals and a psychosocial profile.

Users can also sign up to receive regular e-mail communications on diabetes topics from Novo Nordisk and link to divabetic.org, a diabetes outreach site for women.

Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...